Ranolazine Tablet, Extended Release
Product Images NDC 27241-125

Product Visual Gallery

This gallery contains 3 technical images submitted to the FDA as part of the official labeling for Ranolazine (NDC 27241-125). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Ajanta Pharma Usa Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

1000mg (Ranolazine 1000mg)

Label for Ranolazine Extended-Release Tablets 1000 mg, oral dosage form by Ajanta Pharma USA Inc. The label indicates 60 tablets per package, noting they should be swallowed whole without crushing or chewing. Storage instructions specify 20° to 25°C with permitted excursions, and it includes the NDC 27241-126-02. The tablets are film-coated and made in India.*

FDA Label Image

500mg (Ranolazine 500mg)

Label for Ranolazine Extended-Release Tablets 500 mg by Ajanta Pharma USA Inc. The label states each film-coated tablet contains 500 mg Ranolazine, with instructions to swallow whole without crushing, breaking, or chewing. The package contains 60 tablets. Storage instructions and warnings are also included.*

FDA Label Image

Structure (Ranolazine Structure)

Chemical structure of ranolazine showing its molecular arrangement including an aromatic ring, amide and ether functional groups, and a methoxy substituent, consistent with the active ingredient ranolazine.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.